In the RESPITE trial, riociguat proved to be a viable alternative for patients with PAH not responding to PDE5 inhibitors because of reduced endogenous NO production (Hoeper et al., 2017a). This evidence concerns the gene PDE5A and pulmonary arterial hypertension.